El Net debt/EBITDA de HealthCare Global Enterprises Limited es N/A
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2022, the company operated 22 comprehensive cancer centers, including 1 center in Africa. The company was founded in 1989 and is based in Bengaluru, India.